Milestone Miscalculation: Why Evotec's Second Profit Warning Has Analysts at Loggerheads

RBC sees buying opportunity at €10, Deutsche Bank cautious at €4.50 after Evotec’s second profit warning in four months. Shares hit 52-week low.

Two banks examined the same set of revised projections from Evotec this week. One sees a buying opportunity at a 10-euro price target. The other sees a reason to stay cautious at 4.50 euros. The chasm between those verdicts underscores just how sharply the Hamburg-based biotech's credibility has fractured after its second profit warning in four months.

The shares touched 3.41 euros on Wednesday, clawing just 6.7 percent above a 52-week low of 3.19 euros set the previous day. That leaves the stock down 56 percent from its November 2025 peak of 7.75 euros, with a 30-day annualised volatility reading of 67.1 percent reflecting the frayed nerves. The market capitalisation has shrunk to 895 million euros.

The Case for Patience

RBC Capital's Charles Weston kept his "Outperform" rating and 10-euro target despite describing the latest guidance cut as "another material profit warning." His conviction rests on the underlying performance of the core Discovery & Preclinical Development unit, where net sales rose roughly 28 percent in the first half. Weston acknowledges that Evotec has squandered credibility on expectation management, but he believes the revenue deferrals are timing issues rather than permanent losses.

On the other side, Deutsche Bank's Fynn Scherzler is unimpressed. He reiterates a "Hold" with a 4.50-euro target, pointing out that the warning came just four months after the previous forecast and that Evotec remains overly reliant on a handful of large partnership agreements. The gap between the two price targets — more than 5 euros — illustrates the market's unresolved debate over how much weight to assign to the guidance miss.

The Numbers That Triggered the Split

Evotec released preliminary half-year figures on 13 July. Revenue reached roughly 300.1 million euros, while adjusted EBITDA came in at negative 42.7 million euros. Cash stood at about 465.6 million euros at the end of June.

For the full year, management now expects revenue in a range of 570 million to 610 million euros and an adjusted EBITDA loss of between 70 million and 105 million euros. The company attributed about 40 percent of the shortfall to milestone payments that have been pushed into 2027, a further 45 percent to slower-than-expected progress in negotiating new strategic partnerships, and the remaining 15 percent to lower revenue recognition than anticipated.

Base Business Shows Resilience

Amid the gloom, one bright spot is the performance of Evotec's non-strategic partnership operations. The company reported that net sales in its core Discovery & Preclinical business rose by around 28 percent year-on-year in the first half, driven by higher capacity utilisation at Just – Evotec Biologics and an expanding client base. The cost-saving programme is also on schedule: the group aims to improve its cost base by 75 million euros by the end of 2027, with 20 to 30 percent of that targeted for 2026.

Technicals Offer Little Comfort

The 14-day relative strength index sits at 20.6, a level that typically signals an oversold condition. In a crisis of confidence, however, technicians caution that such readings say little about near-term direction. The stock trades 29.9 percent below its 50-day moving average of 4.86 euros and 37.1 percent below the 200-day line of 5.41 euros. Since the start of the year it has lost 38.6 percent, and over twelve months the decline is 53.4 percent.

A Question That Extends Beyond Evotec

The underlying risk highlighted by these events is structural. The partner-dependent model that was once touted as a lower-risk way to participate in drug development relies on major pharmaceutical companies paying milestone fees on schedule and signing new collaborations at a predictable pace. When those global pharma groups delay or cut spending — as many are doing now — the supposed risk buffer vanishes. Evotec's experience suggests that the entire contract research segment may be more exposed to the investment cycles of its large clients than its proponents once believed.

The company must now prove that the deferred milestones will materialise and that the delayed strategic partnerships will close. Unless it can restore confidence through greater financial transparency and more detailed guidance, the shares will remain a test of how much faith investors place in a promise that has now been broken twice. The full second-quarter results, due on 13 August, will provide the next hard evidence.